Loading
Life sciences · Journal article
Journal of Experimental & Clinical Cancer Research · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Glioblastoma (GB) is an aggressive brain tumor characterized by marked radioresistance and poor clinical outcomes. MicroRNAs (miRNAs) are key post-transcriptional regulators implicated in tumor progression and therapeutic response. Here, we investigated radiation-induced miRNA modulation in patient-derived cancer stem-like cell (CSLC) neurospheres exposed to internal radionuclide therapy using rhenium-188-loaded lipid nanocapsules ( 188 Re-LNC). MiRNA profiling following 188 Re-LNC treatment identified miR-22-3p, miR-197-3p, and miR-574-3p as potential candidates for functional characterization. Lentiviral-mediated overexpression in U87MG cells revealed distinct phenotypes, with miR-22-3p promoting proliferation and clonogenic survival, whereas miR-197-3p primarily enhanced migratory capacity while miR-574-3p had little effect on either phenotype. In an orthotopic murine xenograft model, miR-22-3p and miR-197-3p overexpression accelerated tumor progression and was associated with reduced survival. Notably, upon 188 Re-LNC treatment, miR-22-3p-expressing tumors exhibited pronounced radioresistance, with a complete absence of long-term survivors, while miR-197-3p-expressing tumors remained responsive to therapy. AntagomiR-mediated inhibition of miR-22-3p restored radiosensitivity in vitro and was accompanied by upregulation of the DNA demethylase TET1 that is identified here as a candidate functional target of miR-22-3p. Together, these findings identify miR-22-3p as a critical mediator of GB radioresistance and miR-197-3p as a driver of invasion, supporting their relevance as therapeutic targets and predictive biomarkers to improve radiotherapy stratification and efficacy in GB.